US Patent Issued to Takeda Pharmaceutical on Nov. 25 for "Constrained conditionally activated binding proteins" (California Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,673, issued on Nov. 25, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Constrained conditionally activated binding proteins" was invented by Chad May (San Carlos, Calif.), Robert B. DuBridge (Belmont, Calif.), Maia Vinogradova (San Francisco) and Anand Panchal (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cell...